FDA reviewers flag concerns over Sarepta's gene therapy for DMD

Data presented for Sarepta Therapeutics Inc's experimental gene therapy for a muscle-wasting disorder did not provide unambiguous evidence that the treatment worked, the U.S. Food and Drug Administration's staff reviewers on Wednesday.